热门资讯> 正文
Climb Bio任命道格拉斯·威廉姆斯为主席
2024-11-11 20:11
- Climb Bio (NASDAQ:CLYM) said it has appointed Douglas Williams as its chair.
- Williams will succeed Andrew Levin in the role.
- Williams has over 30 years of executive leadership experience in the biotechnology sector, and formerly served as the president of research and development at Sana Biotechnology and was CEO of Codiak BioSciences.
More on Climb Bio
- Eliem Therapeutics: Recent Strategic Pipeline Restructuring
- Eliem Therapeutics rebrands as Climb Bio with new name and logo
- Eliem Therapeutics appoints Kaplan as COO; Rampal as SVP, Clinical Development
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
